CD44 and prostate cancer: Furthermore, using a comparative analysis of RNA-seq and scRNA-seq from prostate cancers, we identified overexpression of VIM, AHNAK2, ANXA1, ANXA2, CD109, CD44, CD59, GPRC5A, HAS, S100A6, TGFBR2 in both cohorts.